Vertex Pharmaceuticals (1VRTX) Income Statement
Vertex Pharmaceuticals Income Statement
Last quarter (Q2 2026), Vertex Pharmaceuticals's total revenue was $3.33B, an increase of 12.45% from the same quarter last year. In Q2, Vertex Pharmaceuticals's net income was $1.10B. See Vertex Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 12.07B | $ 11.02B | $ 9.87B | $ 8.93B | $ 7.57B | |
| $ 10.27B | $ 9.49B | $ 8.61B | $ 7.85B | $ 6.67B | |
| $ 5.51B | $ 9.72B | $ 4.78B | $ 3.54B | $ 3.89B | |
| Depreciation and Amortization | $ 209.80M | $ 207.20M | $ 181.30M | $ 148.30M | $ 125.60M |
| $ 4.87B | $ 486.30M | $ 4.61B | $ 4.44B | $ 2.92B | |
| $ 4.76B | $ -232.90M | $ 3.83B | $ 4.31B | $ 2.78B | |
| $ -117.50M | $ 481.40M | $ 547.80M | $ -75.00M | $ -51.70M | |
| $ 4.64B | $ 248.50M | $ 4.38B | $ 4.23B | $ 2.73B | |
| $ 3.95B | $ -535.60M | $ 3.62B | $ 3.32B | $ 2.34B | |
| Per Share Metrics | |||||
| Basic EPS | $ 15.46 | $ -2.08 | $ 14.05 | $ 12.97 | $ 9.09 |
| Diluted EPS | $ 15.32 | $ -2.08 | $ 13.89 | $ 12.82 | $ 9.01 |
| Weighted Average Shares Outstanding | 255.70M | 257.50M | 257.70M | 256.10M | 257.70M |
| Weighted Average Shares Outstanding (Diluted) | 258.00M | 257.90M | 260.50M | 259.10M | 259.90M |
Currency in USD